Please login to the form below

Not currently logged in
Email:
Password:

NDA Group appoints new vice president

Dr Werner Van den Eynde will also lead its advisory board

Regulatory affairs consultancy group NDA has appointed Dr Werner Van den Eynde as its new vice president to head up its advisory board providing strategic advice to pharmaceutical clients during its drug development life cycle.

Eynde comes to the Swiss group with international pharmaceutical experience, having held senior positions for the likes of GE Healthcare, Abbott and Solvay Pharmaceuticals.

His new role will see him manage strategy operations and development of the NDA advisory board, including business development, sales, marketing and service development.

He said: “NDA is the perfect platform for anyone who wants to have a positive impact on drug development across the world and the excellent reputation of the NDA advisory board is wide spread.

“Building on an almost twenty year tradition of unbiased advice to drug developing companies, I’m very motivated to continue the NDA success story and expand the advisory board to meet the future demands that science, technology and the regulatory environment put on companies developing therapies for patients.”

Eynde joins the group from Chemo – Exeltis where he was head of R&D, regulatory affairs and pharmacovigilance.

Johan Stromquist, chief executive officer, NDA Group, said: “ With his [Eynde] experience in drug development, following the process from many perspectives, he will be able to add tremendous value to clients in all stages of development, as well as create tailored teams and services of great benefit to the drug development industry.”

6th September 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...